GGrantIndex
← Leaderboards

Aronora, Inc.

Portland, OR

Compare ↔
$39,336,462
Total funding
14
Grants

Funding over time

peak $3.8M · FY2009–25
$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$39,336,462 · 14

By mechanism

R44$38,188,786 · 10
R43$1,147,676 · 4

Investigators at Aronora, Inc.

Investigator-initiatedAll funding

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

Not enough data

Emerging Leaders

6–10 yrs in

1Christina U Lorentz$5,989,8075 gr2Brandon D Markway$224,9971 gr

All-Time

Most funded here, all years

1Erik Ian Tucker$22,365,22913 gr2Christina U Lorentz$5,989,8075 gr3Norah Verbout$5,329,8692 gr4Michael Wallisch$1,130,7111 gr5Brandon D Markway$224,9971 gr6Philberta Yuenhui Leung$157,8331 gr

Largest grants

Antithrombotic Protein C Activator for Hemodialysis$1,493,466
R44 · FY2020 · HL
Contact Pathway Inhibitor to Prevent Vascular Access Failure$1,480,856
R44 · FY2024 · HL
Therapeutic thrombin analogs$1,373,097
R44 · FY2011 · HL
Contact Pathway Inhibitor to Prevent Vascular Access Failure$1,331,056
R44 · FY2025 · HL
Contact Pathway Inhibitor to Prevent Catheter-Related Thrombosis$1,069,527
R44 · FY2025 · HL
Therapeutic factor XI blockade for sepsis$1,000,000
R44 · FY2012 · AI
Factor XII Inhibitor for Surface Initiated Thrombosis$999,930
R44 · FY2020 · HL
Factor XI inhibitor for thrombosis$999,525
R44 · FY2018 · HL
Factor XI inhibitor for thrombosis$999,525
R44 · FY2019 · HL
Antithrombotic Protein C Activator for Hemodialysis$999,415
R44 · FY2022 · HL
Antithrombotic Protein C Activator for Hemodialysis$999,415
R44 · FY2023 · HL
Factor XI inhibitor for thrombosis$999,377
R44 · FY2012 · HL
Therapeutic factor XI blockade for sepsis$999,329
R44 · FY2015 · HL
Therapeutic Protein C Activator for Myocardial Ischemia$999,263
R44 · FY2018 · HL
HLS- Factor XII Inhibitor for Surface Initiated Thrombosis$998,771
R44 · FY2017 · HL
Therapeutic Protein C Activator for Myocardial Ischemia$998,750
R44 · FY2019 · HL
Contact Pathway Inhibitor to Prevent Vascular Access Failure$998,549
R44 · FY2023 · HL
Antithrombotic Protein C Activator for Hemodialysis$998,345
R44 · FY2021 · HL
Therapeutic Protein C Activator for Myocardial Ischemia$998,107
R44 · FY2017 · HL
Therapeutic factor XI blockade for sepsis$997,083
R44 · FY2016 · HL